NEXT-Cue
Neuroxt, Inc. · Decision date Oct 8, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for NEXT-Cue, a 510(k) submitted by Neuroxt, Inc. of Seoul, KR, under number K261805. The decision date is 2026-10-08; the application was received 06/01/2026. The device is listed under the classification name Prognostic Assessment Software Of Mild Cognitive Impairment, with product code QWT, in the Neurology specialty and Neurology review panel. The submission is a Traditional 510(k), not reviewed by a third party, not a combination product, and without an authorized Predetermined Change Control Plan.
SESE means the submission was cleared as substantially equivalent to a predicate device; it is not a PMA approval. The source page does not identify the predicate device, the specific components or changed items, the intended-use wording, or any performance data supporting the equivalence finding. Those details would sit in the underlying 510(k) review documents rather than the database record summarized here.
No clinical, efficacy or patient-selection conclusions are drawn from this record, and none of the missing elements above should be inferred from the clearance alone.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Oct 8, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261805
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Neuroxt, Inc.
- Product code
- QWT
- Decision code
- SESE
- Decision date
- Oct 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prognostic Assessment Software Of Mild Cognitive Impairment.
- Applicant
- Neuroxt, Inc.
- Product code
- QWT
- FDA device class
- 2
FDA decision timeline
K261805 received
Application receipt date recorded by FDA.
K261805 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Neuroxt, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Seoul
Sources and methodology
- Original FDA record: K261805
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records